Literature DB >> 4029021

Human pharmacokinetics and antimicrobial activities of the temocillin epimers.

E A Guest, R Horton, G Mellows, B Slocombe, A J Swaisland, T C Tasker, A R White.   

Abstract

The pharmacokinetics of the epimers of temocillin were investigated in 4 healthy male subjects following intravenous administration of 1g of temocillin disodium (free acid) which contains a R : S epimer ratio of approximately 65 : 35. The R epimer had a 2-fold greater total plasma clearance, a 23% larger volume of distribution and a shorter beta half-life than the S epimer. Intermediate values were obtained for total temocillin (R + S) from high pressure liquid chromatography (HPLC) data. In each plasma sample, the unbound fraction of the R epimer was generally 2-fold higher than that of the S epimer, which is suggested as the reason for the differences in the pharmacokinetic properties of the epimers. The temocillin pharmacokinetic parameters obtained from the microbiological assay data reflect most closely those for the R epimer derived from HPLC data. The resolved R epimer exhibited twice the potency of the S epimer against the microbiological assay organism Pseudomonas aeruginosa NCTC 10701. However, in tests for antibacterial susceptibility, for instance minimum inhibitory concentration (MIC) determinations involving prolonged incubation, there was little difference in the inhibitory activities of the resolved R and S epimers compared with temocillin (R + S), presumably as a consequence of the epimerization of the individual epimers. In contrast, in rapid tests for bactericidal activity, which minimise the effect of epimerization, the R epimer exhibited greater bactericidal activity than the S epimer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029021     DOI: 10.2165/00003495-198500295-00032

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

1.  Renal excretion of R- and S-epimers of moxalactam in dogs.

Authors:  M Nakamura; K Sugeno; R Konaka; H Yamada; T Yoshida
Journal:  J Pharm Sci       Date:  1982-10       Impact factor: 3.534

2.  High-performance liquid chromatographic assay of temocillin and epimerisation of its diastereoisomers.

Authors:  A E Bird; C H Charsley; K R Jennings; A C Marshall
Journal:  Analyst       Date:  1984-09       Impact factor: 4.616

3.  Plasma protein binding and urinary excretion of R- and S-epimers of an arylmalonylamino 1-oxacephem II: In rats.

Authors:  H Yamada; T Ichihashi; K Hirano; H Kinoshita
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

4.  Plasma protein binding and urinary excretion of R- and S-epimers of an arylmalonylamino 1-oxacephem. I: In humans.

Authors:  H Yamada; T Ichihashi; K Hirano; H Kinoshita
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

5.  Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers.

Authors:  R M Brown; R Wise; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

6.  Moxalactam epimer kinetics in children.

Authors:  M C Nahata; D E Durrell; W J Barson
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

7.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

8.  Human pharmacokinetics of temocillin (BRL 17421) side chain epimers.

Authors:  E A Guest; R Horton; G Mellows; B Slocombe; A J Swaisland; T C Tasker
Journal:  J Antimicrob Chemother       Date:  1985-03       Impact factor: 5.790

9.  Epimers of moxalactam: in vitro comparison of activity and stability.

Authors:  R Wise; P J Wills; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.